SLC5A2 and atrial fibrillation: Pooling 16 studies assessing the incidence of AF/AFL (SGLT2 inhibitors, 20,914 patients; placebo, 17,421 patients) showed that SGLT2 inhibitors significantly decreased the incidence of reported AF/AFL events compared with placebo (RR: 0.76; 95% CI 0.65–0.90; p = 0.001; high SOE).